Company intelligence / Profile preview

DSS

Rochester, New York, USA

Ownership: Public · DSS
Development stage: Other

Overview

DSS is a diversified holding company with a strategic focus on emerging opportunities in biotechnology through its subsidiaries. It invests in early-stage biotech firms such as Vivacitas Oncology and operates the wholly owned subsidiary Impact BioMedical, which develops solutions for neurological, oncological, and immuno-related diseases. The company’s business model includes spinning off successful biotech units into IPOs for shareholder value creation.

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Investment partnerships with Vivacitas OncologyCollaborations via subsidiaries not fully detailed publiclyInfusion51a LP

Financials

Market cap: $8.1M
Total revenue: $3.6M
Enterprise value: $46.1M

Beyond the preview

Go deeper on DSS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DSS.

Explore the full profile